Found 968 clinical trials
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Currently Recruiting
Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease
) transplant procedure. cGVHD is a common complication of stem cell transplantation, resulting from the donor cells attacking the transplant recipient's tissues. In oral cGVHD, the tissues in the mouth are
- 38 views
- 22 Dec, 2020
- 1 location

TRANSFORM – B cell non-Hodgkin lymphoma - JCAR017-BCM-003 - US
per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and
- 2946 views
- 05 Jan, 2021
- 10 locations
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
Oncology
-
Currently Recruiting
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease
- 300 views
- 08 Dec, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Currently Recruiting
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the
- 57 views
- 22 Dec, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Oncology
-
Currently Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
cell transplant with fewer complications. Objectives: To evaluate a new method of stem cell transplantation that may reduce the possibly of severe side effects
- 86 views
- 22 Dec, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Oncology
-
Currently Recruiting
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
people who need stem cell transplants. Eligibility: Individuals who are scheduled to have a stem cell transplant. Design:
- 79 views
- 22 Dec, 2020
- 1 location

PILOT - B cell non-Hodgkin lymphoma - TRANSCEND-PILOT-017006 - US
single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities
- 2758 views
- 15 Dec, 2020
- 12 locations
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Oncology
-
Currently Recruiting
Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphamide for GVHD Prophylaxis
inserted in the neck or chest Medicines for side effects Chemotherapy over 8 days and radiation 1 time Stem cell transplant over 4 hours Up to 6 months after
- 57 views
- 22 Dec, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Oncology
-
Currently Recruiting
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
. Researchers are testing ways to make stem cell transplant safer and more effective. Objective: To test if treating people with SAA or MDS with a co-infusion of blood
- 57 views
- 22 Dec, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
Oncology
-
Currently Recruiting
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
the patient s healthy tissues. The average hospital stay after stem cell transplantation is 3 to 4 weeks. Patients return for frequent follow-up visits for the first 2 to 4 months after
- 48 views
- 22 Dec, 2020
- 1 location